Silodosin in the treatment of benign prostatic hyperplasia

@inproceedings{Rossi2010SilodosinIT,
  title={Silodosin in the treatment of benign prostatic hyperplasia},
  author={Maxime Rossi and Thierry Roumegu{\`e}re},
  booktitle={Drug design, development and therapy},
  year={2010}
}
Benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) are highly prevalent in older men. Medical therapy is the first-line treatment for LUTS due to BPH. Alpha-adrenergic receptor blockers remain one of the mainstays in the treatment of male LUTS and clinical BPH. They exhibit early onset of efficacy with regard to both symptoms and flow rate improvement, and this is clearly demonstrated in placebo-controlled trials with extensions out to five years. These agents… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Silodosin: An orally active selective α 1 -adrenoceptor antagonist for benign prostatic hyperplasia

  • Guay DRP
  • Aging Health
  • 2009

Similar Papers

Loading similar papers…